Abstract
Axl is a tyrosine kinase receptor that is commonly overexpressed in many cancers. As such, Axl represents an attractive therapeutic target. The transfer of engineered T cell expressing chimeric antigen receptor (CAR) is an exciting cancer therapeutic approach that shows high efficacy against cancers in clinical trials, especially for B cell malignancies. Furthermore, recently developed synthetic Notch (synNotch) receptor has demonstrated potential in enhancing the specificity of CAR T cell therapy and delivering therapeutic payloads to tumors in an antigen-dependent manner. Therefore, a CAR or synNotch against Axl could be a valuable therapeutic reagent against many cancers. Here, we develop a single-chain variable fragment from a humanized monoclonal antibody against Axl. The scFv is attached to CD3ζ, CD28, and 4-1BB signaling domains to generate an anti-Axl CAR. When introduced into human primary T cells, the anti-Axl CAR can lead to cytokine production and cell killing in response to tumor cells expressing Axl. Moreover, an anti-Axl synNotch generated using the same scFv can be activated with Axl expressing tumor cells. Given the fact that Axl is an important cancer therapeutic target, these receptors could be valuable reage...Continue Reading
References
Sep 1, 1994·Stem Cells·S F ZieglerM R Alderson
Dec 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Matthew H WilsonAlfred L George
Apr 22, 2009·Cell·Raphael Kopan, Maria Xenia G Ilagan
Jul 7, 2010·Cell·Mark A Lemmon, Joseph Schlessinger
Jul 7, 2010·Oncogene·X YeL Pei
Mar 14, 2012·Oncogene·J D PaccezL F Zerbini
Jul 4, 2012·Nature Genetics·Zhenfeng ZhangTrever G Bivona
Oct 24, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lauren Averett ByersJohn V Heymach
Mar 22, 2013·Science Translational Medicine·Renier J BrentjensMichel Sadelain
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Apr 4, 2013·Cancer Discovery·Michel SadelainIsabelle Rivière
May 21, 2013·Biochemical and Biophysical Research Communications·Ju HanTingsheng Peng
May 25, 2013·Science·Xuefeng Wang, Taekjip Ha
Sep 24, 2013·Oncogene·M A CichońE A O'Toole
Nov 28, 2013·Annual Review of Medicine·David M BarrettCarl H June
Jan 16, 2014·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Dan LiPeter S Conti
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Mar 13, 2014·ACS Synthetic Biology·Nichole M DaringerJoshua N Leonard
Aug 20, 2014·Cancer Research·Toni M BrandDeric L Wheeler
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Oct 23, 2014·Oncotarget·Xiaoliang WuBalazs Halmos
Jul 17, 2015·British Journal of Cancer·H YuP S Gill
Nov 12, 2015·Journal of Medicinal Chemistry·Samuel H MyersAsier Unciti-Broceta
Feb 3, 2016·Cell·Kole T RoybalWendell A Lim
May 12, 2016·Nano Letters·Farhan ChowdhuryTaekjip Ha
Oct 4, 2016·Cell·Kole T RoybalWendell A Lim
Jan 1, 2017·BMJ Open·Xiao-Yi TangHu Chen
Jan 11, 2017·British Journal of Cancer·Carl M GayLauren Averett Byers
Citations
Nov 7, 2019·Molecular Cancer·Chenjing ZhuXiawei Wei
Nov 15, 2019·HemaSphere·Astrid Holzinger, Hinrich Abken
May 1, 2020·Cytometry. Part B, Clinical Cytometry·Elena MaryamchikMarcela V Maus
Sep 25, 2018·Expert Opinion on Therapeutic Targets·Wenting Du, Rolf A Brekken
Jan 23, 2019·Current Hematologic Malignancy Reports·Stacie IttershagenDavid Lebwohl
May 3, 2020·Nature Communications·Zhifu WangJianhong Zhu
Oct 1, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S TahmasebiA Esmaeilzadeh
Dec 10, 2020·Nature Reviews. Drug Discovery·Samarpan MajumderLucio Miele
Sep 16, 2020·British Journal of Cancer·Hans RaskovIsmail Gögenur
Mar 23, 2021·Advanced Science·Peixiang MaRichard A Lerner
Apr 4, 2021·Molecular Cancer Research : MCR·Wenting DuRolf A Brekken